DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumor
Lung Neuroendocrine Neoplasm

Interventions: Procedure: NETest

First Posted Date: 2016-10-31

Last Posted Date: 2021-08-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 105

Registration Number: NCT02948946

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Phase 2

Active, not recruiting

Conditions: Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
Soft Tissue Sarcoma

Interventions: Drug: nab-Paclitaxel
Drug: Gemcitabine

First Posted Date: 2016-10-26

Last Posted Date: 2025-03-14

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 59

Registration Number: NCT02945800

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 11 locations

Spanish-Language Smoking Cessation Trial

Not Applicable

Completed

Conditions: Smoking Cessation

Interventions: Behavioral: Spanish-Language Version of the Stop Smoking for Good
Behavioral: NCI-Produced Spanish-language Self-help Booklet

First Posted Date: 2016-10-26

Last Posted Date: 2022-11-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 1417

Registration Number: NCT02945787

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

Phase 1

Completed

Conditions: Rectal Adenocarcinoma
Rectal Cancer

Interventions: Drug: Lenvatinib
Drug: Capecitabine
Radiation: External Radiation Therapy (XRT)

First Posted Date: 2016-10-17

Last Posted Date: 2022-05-31

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT02935309

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Phase 2

Terminated

Conditions: Carcinoma in Situ of Bladder
Bladder Cancer

Interventions: Drug: Durvalumab
Procedure: Cystoscopy with Biopsy

First Posted Date: 2016-09-15

Last Posted Date: 2022-07-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 17

Registration Number: NCT02901548

Locations: 🇺🇸
Mount Sinai Medical Center Miami, Miami Beach, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Phase 1

Completed

Conditions: Graft Vs Host Disease
GVHD

Interventions: Drug: Pacritinib
Drug: Sirolimus
Drug: Tacrolimus
Procedure: Allogenic hematopoietic cell transplant (alloHCT)

First Posted Date: 2016-09-07

Last Posted Date: 2024-12-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 40

Registration Number: NCT02891603

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

Early Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Survivin Vaccine
Procedure: Autologous Hematopoietic Cell Transplantation
Biological: Prevnar 13
Drug: Granulocyte-colony Stimulating Factor

First Posted Date: 2016-08-01

Last Posted Date: 2022-11-14

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 14

Registration Number: NCT02851056

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Phase 1

Completed

Conditions: Malignant Glioma

Interventions: Radiation: Hypofractionated Stereotactic Irradiation
Drug: Nivolumab
Drug: Bevacizumab
Drug: Ipilimumab

First Posted Date: 2016-07-12

Last Posted Date: 2023-01-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 33

Registration Number: NCT02829931

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Phase 2

Completed

Conditions: Biliary Tract Neoplasms
Biliary Tract Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2016-07-12

Last Posted Date: 2025-05-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 54

Registration Number: NCT02829918

Locations: 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Phase 1

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Panobinostat
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-06-16

Last Posted Date: 2017-04-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT02802163

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy